Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults

Patrocinadores

Patrocinador principal: Glaxo Wellcome

Fuente NIH AIDS Clinical Trials Information Service
Resumen breve

The purpose of this study is to compare GW433908 and nelfinavir when each is given with abacavir and lamivudine to HIV patients who have not taken antiretroviral drugs.

Descripción detallada

Patients are randomized in a 2:1 scheme to 1 of 2 treatment groups. Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC. Patients undergo safety and efficacy assessments at the Screening Visit, Day 1 (Entry), and Weeks 1, 2, 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter. A follow-up visit is performed 4 weeks after the permanent discontinuation of study drug. Detailed assessments for the development of lipodystrophy/fat redistribution occur at Day 1, Week 24, Week 48, and every 16 weeks thereafter. Patients have examinations and laboratory tests performed at visits.

Estado general Unknown status
Fecha de inicio November 2000
Fase Phase 3
Tipo de estudio Interventional
Inscripción 210
Condición
Intervención

Tipo de intervención: Drug

Nombre de intervención: Abacavir sulfate

Tipo de intervención: Drug

Nombre de intervención: Nelfinavir mesylate

Tipo de intervención: Drug

Nombre de intervención: Lamivudine

Tipo de intervención: Drug

Nombre de intervención: GW433908

Elegibilidad

Criterios:

Inclusion Criteria

Patients may be eligible for this study if they:

- Are at least 13 years old (consent of parent or guardian required if under 18).

- Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children.

- Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRT) or protease inhibitor (PI).

- Have a viral load (amount of HIV in the blood) of 5,000 copies/ml or more, or have a positive result at the screening visit.

Exclusion Criteria

Patients will not be eligible for this study if they:

- Abuse drugs or alcohol in a way that would interfere with the study, in the opinion of the doctor. Patients stable on methadone will be considered for participation.

- Have an active/acute CDC Category C event.

- Are unable to absorb or take medicines by mouth.

- Are pregnant or breast-feeding.

- Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient.

- Have had pancreatitis or hepatitis within the last 6 months.

- Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study.

- Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken.

- Have received HIV vaccine within 3 months before the study drug will be taken.

- Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study.

- Have received experimental treatments.

- Have allergies which might interfere with the study, in the opinion of the doctor.

Género: All

Edad mínima: 13 Years

Edad máxima: N/A

Voluntarios Saludables: No

Ubicación
Instalaciones:
East Bay Clinical Trial Ctr | Concord, California, 94520, United States
Ocean View Internal Medicine | Long Beach, California, 90803, United States
Florida ID Group | Orlando, Florida, 32801, United States
Hillsborough County Health Dept | Tampa, Florida, 33602, United States
Clinical Pharmacology Services | Tampa, Florida, 33617, United States
Veterans Affairs Med Ctr of North Chicago | Chicago, Illinois, 60064, United States
Univ of Kansas Med Ctr | Kansas City, Kansas, 661607415, United States
Saint Michael's Med Ctr | Newark, New Jersey, 07102, United States
UMDNJ - New Jersey Med School | Newark, New Jersey, 071032757, United States
Bronx Municipal Hosp Ctr/Jacobi Med Ctr | Bronx, New York, 10461, United States
Addiction Research and Treatment Corp | Brooklyn, New York, 11201, United States
Brookdale Univ Hosp and Med Ctr | Brooklyn, New York, 112123198, United States
Gervais Frechette | New York, New York, 10011, United States
Howard Grossman | New York, New York, 10011, United States
Mount Sinai School of Medicine | New York, New York, 10029, United States
Univ of Rochester Med Ctr | Rochester, New York, 14642, United States
SMO-USA Inc | Charlotte, North Carolina, 28211, United States
Advanced Clinical Trials Inc | Eugene, Oregon, 97401, United States
Thomas Jefferson Univ | Philadelphia, Pennsylvania, 19107, United States
Univ of Texas Med Branch | Galveston, Texas, 775550835, United States
MacGregor Med Association | Houston, Texas, 77054, United States
Walter Gaman | Irving, Texas, 75038, United States
Southwest Texas Methodist Hosp | San Antonio, Texas, 78229, United States
Ubicacion Paises

United States

Fecha de verificación

July 2001

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Información de diseño del estudio

Modelo de intervención: Parallel Assignment

Propósito primario: Treatment

Fuente: ClinicalTrials.gov